BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies
Rivaroxaban Versus Vitamin K-Antagonist (VKA) in Thromboprophylaxis of Patients With Atrial Fibrillation: Patient Preference Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Many Locations, Germany
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
A.General Criteria (Group 1and Group2):
- diagnosed non-valvular AF
- older than 18 years
- general capability and willingness to perform a structured patient interview in German
- no participation in any other clinical or observational study over the last 3 month
Additional criteria for Group1 (VKA-experienced):
- active VKA-therapy for at least 3 month without significant interruptions
- in case of perioperative interruption VKA treatment should not have been hold for more than two weeks.
Additional criteria for Group2 (rivaroxaban-experienced patients):
- active rivaroxaban-therapy for at least 3 month without significant interruptions
- in case of perioperative interruption VKA treatment should not have been hold for more than two weeks.
Exclusion Criteria:
- participation in any other clinical or observational study over the last 3 month
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Group 1
300 AF patients, with at least 3 month of anticoagulation therapy with VKAs (VKA-experienced patients)
|
common use, no requirements (real life situation)
|
|
Group 2
300 AF patients, with at least 3 month of rivaroxaban therapy (rivaroxaban-experienced patients)
|
common use, no requirements (real life situation)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
A prescription of patient preferences pattern including 5 attributes for Discrete-Choice-Experiment(DCE)-design in patients with atrial fibrillation
Time Frame: Within 1-4 weeks after patient enrollement
|
Attributes and values in relation to the DCE-Choice-Set.
The patient will receive a "test card" with the following attributes: bridging of anticoagulation, regular anticoagulation control, limitations to eating behaviour and alcohol consumption, once vs. twice daily intake of medication, neutral comparator for quantification display of preference: distance to therapy practice
|
Within 1-4 weeks after patient enrollement
|
|
Patient relevant burden/benefit due to anticoagulation using the ACTS-questionnaire
Time Frame: At study entry
|
At study entry
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 17019
- OR-ITW-01-13 (Other Identifier: Company internal)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.